Christopher Olsen
Research Assistant II, Value & Evidence
Expertise:
Christopher is a Research Assistant II in the Evidence Synthesis group at EVERSANA.
Christopher has been with EVERSANA since 2021 where he has supported systematic and targeted literature reviews across a variety of disease areas including prostate cancer, breast cancer, lymphoma, multiple myeloma, Alzheimer’s disease, and atherosclerotic cardiovascular disease. He has experience in various applications of literature reviews, such as systematic reviews for use within Health Technology Assessment submissions or targeted reviews with focus on surrogacy outcome relationships. In addition, he has supported projects with feasibility assessments, indirect treatment comparisons, and cost-effectiveness analysis components. Furthermore, he has contributed to development of manuscripts and conference materials for publication.
Christopher obtained an Honours Bachelor of Health Sciences (BHSc) degree from Queen’s University. His studies focused on applied research methodologies in health sciences, molecular basis of biology, pharmacology/toxicology/therapeutics, and the anatomical/physiological basis of health and disease.
Articles by Christopher Olsen
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations. The Value & Evidence team […]
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national […]